Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CEACAM1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CEACAM1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CEACAM1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CEACAM1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CEACAM1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CEACAM1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CEACAM1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001056322 | Liver | HCC | negative regulation of phosphorus metabolic process | 259/7958 | 442/18723 | 4.29e-12 | 1.92e-10 | 259 |
GO:004593622 | Liver | HCC | negative regulation of phosphate metabolic process | 258/7958 | 441/18723 | 6.00e-12 | 2.60e-10 | 258 |
GO:007137521 | Liver | HCC | cellular response to peptide hormone stimulus | 179/7958 | 290/18723 | 2.54e-11 | 9.88e-10 | 179 |
GO:004232622 | Liver | HCC | negative regulation of phosphorylation | 227/7958 | 385/18723 | 3.98e-11 | 1.52e-09 | 227 |
GO:005134822 | Liver | HCC | negative regulation of transferase activity | 166/7958 | 268/18723 | 8.97e-11 | 3.18e-09 | 166 |
GO:190165321 | Liver | HCC | cellular response to peptide | 211/7958 | 359/18723 | 2.86e-10 | 9.63e-09 | 211 |
GO:001604921 | Liver | HCC | cell growth | 269/7958 | 482/18723 | 1.84e-09 | 5.35e-08 | 269 |
GO:003367322 | Liver | HCC | negative regulation of kinase activity | 144/7958 | 237/18723 | 9.76e-09 | 2.45e-07 | 144 |
GO:000193322 | Liver | HCC | negative regulation of protein phosphorylation | 196/7958 | 342/18723 | 1.95e-08 | 4.63e-07 | 196 |
GO:004873222 | Liver | HCC | gland development | 242/7958 | 436/18723 | 2.26e-08 | 5.28e-07 | 242 |
GO:006201222 | Liver | HCC | regulation of small molecule metabolic process | 190/7958 | 334/18723 | 6.77e-08 | 1.40e-06 | 190 |
GO:007233021 | Liver | HCC | monocarboxylic acid biosynthetic process | 129/7958 | 214/18723 | 1.08e-07 | 2.09e-06 | 129 |
GO:000155821 | Liver | HCC | regulation of cell growth | 228/7958 | 414/18723 | 1.34e-07 | 2.55e-06 | 228 |
GO:000646912 | Liver | HCC | negative regulation of protein kinase activity | 126/7958 | 212/18723 | 4.55e-07 | 7.49e-06 | 126 |
GO:004218021 | Liver | HCC | cellular ketone metabolic process | 123/7958 | 211/18723 | 2.52e-06 | 3.37e-05 | 123 |
GO:00192162 | Liver | HCC | regulation of lipid metabolic process | 181/7958 | 331/18723 | 4.58e-06 | 5.79e-05 | 181 |
GO:00301932 | Liver | HCC | regulation of blood coagulation | 46/7958 | 66/18723 | 7.12e-06 | 8.47e-05 | 46 |
GO:000663321 | Liver | HCC | fatty acid biosynthetic process | 96/7958 | 163/18723 | 1.71e-05 | 1.85e-04 | 96 |
GO:19000462 | Liver | HCC | regulation of hemostasis | 46/7958 | 68/18723 | 2.43e-05 | 2.56e-04 | 46 |
GO:003009922 | Liver | HCC | myeloid cell differentiation | 200/7958 | 381/18723 | 4.64e-05 | 4.49e-04 | 200 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CEACAM1 | SNV | Missense_Mutation | novel | c.1110N>C | p.Glu370Asp | p.E370D | P13688 | protein_coding | tolerated(0.67) | benign(0.05) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
CEACAM1 | insertion | Nonsense_Mutation | novel | c.592_593insCTTAGTTGGTTTTTTTTGGTT | p.Arg198delinsThrTerLeuValPhePheGlyTrp | p.R198delinsT*LVFFGW | P13688 | protein_coding | | | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CEACAM1 | deletion | Frame_Shift_Del | novel | c.235delN | p.Ile79LeufsTer2 | p.I79Lfs*2 | P13688 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CEACAM1 | SNV | Missense_Mutation | novel | c.1332N>G | p.Ile444Met | p.I444M | P13688 | protein_coding | tolerated(0.08) | possibly_damaging(0.605) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CEACAM1 | SNV | Missense_Mutation | rs150099950 | c.944N>T | p.Thr315Met | p.T315M | P13688 | protein_coding | tolerated(0.21) | benign(0.255) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CEACAM1 | SNV | Missense_Mutation | | c.29N>C | p.Arg10Thr | p.R10T | P13688 | protein_coding | tolerated(0.06) | possibly_damaging(0.465) | TCGA-VS-A8EI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CEACAM1 | SNV | Missense_Mutation | novel | c.521C>T | p.Thr174Ile | p.T174I | P13688 | protein_coding | tolerated(0.14) | possibly_damaging(0.734) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CEACAM1 | SNV | Missense_Mutation | | c.1080C>A | p.Phe360Leu | p.F360L | P13688 | protein_coding | tolerated(1) | benign(0.015) | TCGA-AG-A01N-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | SD |
CEACAM1 | SNV | Missense_Mutation | novel | c.461C>T | p.Ser154Phe | p.S154F | P13688 | protein_coding | deleterious(0.02) | possibly_damaging(0.838) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CEACAM1 | SNV | Missense_Mutation | rs749934399 | c.89C>T | p.Pro30Leu | p.P30L | P13688 | protein_coding | tolerated(0.4) | benign(0.017) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
634 | CEACAM1 | KINASE, CELL SURFACE, DRUGGABLE GENOME | | CHEMOKINES | | 15937057 |
634 | CEACAM1 | KINASE, CELL SURFACE, DRUGGABLE GENOME | | ARCITUMOMAB | ARCITUMOMAB | |
634 | CEACAM1 | KINASE, CELL SURFACE, DRUGGABLE GENOME | | RETINOID | | 8609714 |
634 | CEACAM1 | KINASE, CELL SURFACE, DRUGGABLE GENOME | | RETINOIC ACID | | 15364113 |
634 | CEACAM1 | KINASE, CELL SURFACE, DRUGGABLE GENOME | | ARCITUMOMAB | ARCITUMOMAB | |